Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 6, Number 6—December 2000

Perspective

Evidence Against Rapid Emergence of Praziquantel Resistance in Schistosoma haematobium, Kenya

Charles H. King*, Eric M. Muchiri†, and John H. Ouma†
Author affiliations: *Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio, USA; †Ministry of Health, Nairobi, Kenya

Main Article

Table 1

Effectiveness of praziquantel (PZQ) in eliminating Schistosoma haematobium infection, Msambweni, Coast Province, Kenya, 1984–1992

Patient's infection and treatment status 1984 1985 1986 1987 1989 1990 1991
Egg-positive urine,
Given PZQ, never previously treated 17%
(97 to 1.5)
n = 981 12%
(33 to 1.5)
n = 51 34%
(29 to 3.7)
n = 82 - 15%
(18 to 1.5)
n = 352 4%
(22 to 1.1)
n = 292 35%
(24 to 4)
n = 274
Egg-positive urine,
Given PZQ, had 1 PZQ treatments - 13%
(10 to 1.5)
n = 111 38%
(16 to 2.6)
n = 47 - 10%
(19 to 1.1)
n = 68 2%
(14 to 1.0)
n = 73 29%
(13 to 2.8)
n = 64
All egg-positive, PZQ-treated patients 17%
(97 to 1.5)
n = 981 13%
(15 to 1.5)
n = 162 35%
(24 to 3.3)
n = 129 - 14%
(19 to 1.4)
n = 420 4%
(20 to 1.1)
n = 365 34%
(22 to 3.8)
n = 338
Infection rate
(egg - to egg + conversion) 15% 9% 11% 11% 13% 10% 21%
All patients, treated and untreated 18%
n = 3,196 12%
n =2,498 14%
n = 2,372 19%
n = 1,968 14%
n = 1,398 13%
n = 2,579 24%
n = 1,938

aPZQ = praziquantel.

Main Article

TOP